milvexian
janssen,bms
['milvexian', '$jnj', '$bmy']
jp stock perspective,best case scenario (i.e., ~15% incremental efficacy, no major bleed signal,broad phase 3 program announced for milvexian), $bmy shares up 3-4% and $jnj up ~2% mixed update (efficacy limited to narrow subgroup of patients, etc.leave shares flat to downmodestly 
BIOTECH man LONGTERM FOCUS many positions-also trade around my CORE holdings my opinion only do your own research with me???? https://t.co/N54wXNIEHo